Full Press Release Details
Case Study: bioAffinity Technologies' CyPath Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive
Lung improves diagnostic clarity in patients with multiple lung nodules
this case study, CyPath Lung "Unlikely Malignancy" result supported physician's decision
to wait before ordering an invasive lung biopsy
a clinical study, noninvasive CyPath Lung test demonstrated 92% sensitivity, 87% specificity and 88% accuracy for detecting
lung cancer in small nodules less than 20 millimeters
ANTONIO, TX - March 17, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing
noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study that highlights the benefit
of adding CyPath Lung, a noninvasive test for lung cancer, to the diagnostic pathway for a high-risk patient with
multiple pulmonary nodules.
patient is a 71-year-old former 20-pack-year smoker with a history of pneumonia in the right lower lobe. His current medical condition
includes obesity and mild restrictive lung disease. Low dose CT scans revealed scattered pulmonary nodules, with one measuring 7 millimeters
(mm), a size that has a greater potential for being cancerous and often leads to invasive bronchoscopy or biopsy.
small nodules in a high-risk patient pose a diagnostic challenge, which can be exacerbated by the patient's understandable anxiety
about a potential cancer," said Daya Nadarajah, MD, the patient's pulmonologist. "In this case, the patient's
CyPath Lung result was negative, indicating a low likelihood of malignancy, and together both the patient and I were
comfortable in waiting for a follow-up CT scan in three months."
follow-up scan in October 2025 showed the suspicious nodules in the right upper lobe had resolved, indicating benign inflammation, and
a small nodule located in the fissure between the upper and lower right lobes remained unchanged.
"This is another patient case study that illustrates how CyPath Lung provides accurate results and greater confidence
in pulmonary nodule management, supporting physician decision-making, reducing patient anxiety, and lowering healthcare costs by avoiding
expensive, invasive and often risky procedures when they are not necessary," said Gordon Downie, MD, PhD, Chief Medical Officer
of bioAffinity Technologies.
Lung by bioAffinity Technologies is a noninvasive test designed to aid in the early detection of lung cancer in patients at high risk
for the disease. CyPath Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell
populations in patient sputum that may indicate malignancy. CyPath Lung incorporates a fluorescent porphyrin that is
preferentially taken up by cancer and cancer-related cells. In a clinical study, CyPath Lung demonstrated 92%
sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small indeterminate
lung nodules less than 20 millimeters.
bioAffinity Technologies, Inc.
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum
cancer treatments. The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity,
specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed
Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical
Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare & Medicaid Services. For more information, visit
statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws.
Words such as "may," "might," "will," "should," "believe," "expect,"
"anticipate," "estimate," "continue," "predict," "forecast," "project,"
"plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are
forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult
to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied
by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include,
among others, the ability of CyPath Lung to indicate the probability of lung cancer, CyPath Lung providing
confidence in a proposed course of action for high-risk patients, the ability of CyPath Lung to determine if cancer is
present or if the patient is cancer-free, the ability of CyPath Lung to lower healthcare costs, and the other factors
discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the
SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as
they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking
statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements.
The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to
update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities